Ana Laura Ortega Granados - Medical Oncology Department, Hospital Universitario de Jaén

S. Peters,A.L.O. Ortega Granados,F. de Marinis,G. Lo Russo, M. Schenker, E. Arriola, J.M. Puig, D.H. Lee, M. Reck, Z. Szijgyarto, E. Buss, N. Stjepanovic,

Annals of Oncology (2023): S1309-S1309

引用0浏览0引用

1995P Long-term benefit of atezolizumab plus chemotherapy in extensive stage small cell lung cancer (ES-SCLC): Exploratory analysis from the IMfirst study

M.R. García-Campelo, M. Dómine,J. de Castro Carpeño,A.L. Moreno Vega,S. Ponce Aix, E. Arriola, E. Carcereny, M. Majem, G. Huidobro Vence,E. Esteban Gonzalez,J. Fuentes Pradera,A.L.O. Ortega Granados,

Annals of Oncology (2023): S1064-S1065

引用1浏览0引用

1468P Patients’ perspective on tolerability of dostarlimab in NSCLC: Patient-reported outcomes from the phase II PERLA trial

M. Reck,A.L.O. Ortega Granados, F. de Marinis, Q. Shen, S.H. Boklage, C. Dabrowski, L. Cho, O. Meyers

Annals of Oncology (2023): S832-S833

引用0浏览0引用

153P Descriptive analysis of the location of point mutations in BRCA and the risk of breast or ovarian cancer diagnosis

P. Torres-Mozas, F. Galvez Montosa,N. Luque Caro, F.J.G. Verdejo,A.L.O. Ortega Granados, J. Requena Aguilar, J.Z. Benoit Perejón, R. Garcia Munoz, G.P. Vinueza Hidalgo, I. Fernández Ros, P. Sanchez-Rovira

Annals of Oncology (2023): S242-S242

引用0浏览0引用

Treatment Beyond Progression with Atezolizumab in Extensive-Stage SCLC: Exploratory Analysis from the IMfirst Study